RRMS Updates From ACTRIMS-ECTRIMS 2026

RRMS Updates From ACTRIMS-ECTRIMS 2026

Dr Shiv Saidha, of Johns Hopkins University School of Medicine, reviews key multiple sclerosis (MS) studies presented at the 2026 Joint ACTRIMS-ECTRIMS Meeting.He begins with the phase 3 REMODEL-1 and REMODEL-2 trials, which showed that remibrutinib reduced annualized relapse rates by 35.2% and 31.2%, respectively, compared to teriflunomide. A pooled analysis found a 29.2% reduction in the risk for 6-month confirmed disability progression, which was of nominal statistical significance. No liver safety signal was observed.Next, he reviews phase 3 fenebrutinib analyses from FENhance 1 and -2 in relapsing MS, and FENtrepid in primary progressive MS. Fenebrutinib reduced slowly expanding lesion volume by 30.5% vs teriflunomide in relapsing MS, and by 27.5% vs ocrelizumab in primary progressive MS. In relapsing MS, it also reduced the odds of a net increase in paramagnetic rim lesions by 62% vs teriflunomide.He also discusses the phase 4 MINORE study of women with MS treated with ocrelizumab around pregnancy. B-cell repopulation predominantly involved naive and transitional cells, and serum neurofilament light chain (NfL) peaked at delivery and subsequently declined, highlighting the need to consider peripartum physiology when interpreting NfL levels.Finally, Dr Saidha examines research comparing originator and biosimilar natalizumab that found discordance between two JC virus antibody assays. These discrepancies may affect risk assessment and treatment decisions for progressive multifocal leukoencephalopathy.

Original Source

Read the full article at Medscape →

KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.